Abstract: The present invention provides a detection chip for quantitative detection of neutralizing antibody and manufacturing method thereof. A sensing layer is disposed on a circuit layer. A shielding layer corresponds a shielding part on the sensing layer to form a sensing area. The surface of the sensing area is hydroxylated to form a self-assembled monolayer film including the aldehyde group. A protein solution is dripped on the sensing area. An external electric field is applied to the sensing layer at an external angle with respect to the normal of the substrate to deflect protein molecules in the protein solution correspondingly. This structure can be applied to rapid and quantitative detection. According to various embodiments of the present invention, the sensing efficiency of the detection chip can be enhanced.

Abstract: A method for performance optimization of protein chips produced under an external electric field applied in different directions and a device that provides the external electric field in different directions are revealed. Firstly a plurality of protein chips is produced under an external electric field applied in different directions. Then a binding force between protein molecule on the protein chip and a ligand is measured and compared. Thus an angle of the external electric field applied that achieves performance optimization while using the protein molecule to produce the protein chips is found out. The device providing the external electric field in different directions includes a rotatable electric field support rotating around a carrier used for loading the protein chips. The electric field support is disposed with electrodes for providing the protein chips on the carrier the external electric field in different directions.

Abstract: The present invention relates to a quinic acid derivative, preparation process of the same and pharmaceutical uses thereof. The quinic acid derivative has a quinic acid-like structure which binds to CD28, blocks T-cell signal 2 pathway via CD28, and suppresses T-cell activation. The C-1 carboxyl group, the C-3 hydroxyl group and the C-4 hydroxyl group of quinic acid are modified to attenuate the cytotoxicity of the quinic acid derivative. The preparation process of the quinic acid derivative comprises 2 steps of: treating quinic acid with the first reagent in the presence of the acid catalyst to form an immediate; and treating the immediate with the second reagent to from the quinic acid derivative. With the ability to suppress T-cell activation, the quinic acid derivative is used to treats an autoimmune disease, an allergy, transplant rejection or other related immune disorder.

Abstract: The present invention relates to a quinic acid derivative, preparation process of the same and pharmaceutical uses thereof. The quinic acid derivative has a quinic acid-like structure which binds to CD28, blocks T-cell signal 2 pathway via CD28, and suppresses T-cell activation. The C-1 carboxyl group, the C-3 hydroxyl group and the C-4 hydroxyl group of quinic acid are modified to attenuate the cytotoxicity of the quinic acid derivative. The preparation process of the quinic acid derivative comprises 2 steps of: treating quinic acid with the first reagent in the presence of the acid catalyst to form an immediate; and treating the immediate with the second reagent to from the quinic acid derivative. With the ability to suppress T-cell activation, the quinic acid derivative is used to treats an autoimmune disease, an allergy, transplant rejection or other related immune disorder.

Abstract: A polypeptide for preventing and treating cell hyperplasia is applied to preventing potential objects from cell hyperplasia and treating objects having cell hyperplasia. The polypeptide comprises an amino acid sequence listed as SEQ ID NO: 1. The amino acid sequence can effectively inhibit growth of lung cancers. The polypeptide would not cause significant evil reactions or obvious side effects even though it is applied at a high dose (50 mg/Kg) and a high frequency (5 times per week).

Abstract: A method for drug screening is provided. An atomic force microscopy (AFM) is used to obtain quantitative difference. At least one receptor is immobilized on a probe of the AFM and at least one ligand is immobilized on chips. By flowing a candidate drug on the chips or even applying different candidate drugs to different areas of each chip, drug screening is processed through measuring the binding force between the receptor and the ligand. Multiple drugs can be screened without weakening activity of the proteins during repeated drug screening processes. The drug screening process is cost saved and has high quality. Highly effective protein chips can be developed based on the present disclosure.

Abstract: The present invention provides a method of treating fungal infection by administering a pharmaceutical composition comprising an extract of the leaf of M. oleifera as the sole active component.

Abstract: A novel method of screening herbal composition for a pharmaceutically active component of interest (“target component”) comprises: immobilizing a plurality of receptors of interest on a chip; flowing the herbal composition through the chip to allow binding of the target component with the receptors; disassociating the bound target component from the immobilized receptors on the chip; profiling the disassociated target component by HPLC; and identifying the target component based on the HPLC profile of the disassociated target component.

Abstract: Disclosed is a cell lytic polypeptide that has a region capable of forming an amphipathic alpha helix and a net charge of +12 or more, or that contains 3 regions, each capable of forming an amphipathic alpha helix. A nucleic acid encoding the polypeptide is also disclosed. Also within the scope of this invention are a pharmaceutical composition containing the polypeptide or nucleic acid and a pharmaceutically acceptable carrier, and a method for treating a cellular proliferative disorder.

Abstract: Disclosed is a cell lytic polypeptide that has a region capable of forming an amphipathic alpha helix and a net charge of +12 or more, or that contains 3 regions, each capable of forming an amphipathic alpha helix. A nucleic acid encoding the polypeptide is also disclosed. Also within the scope of this invention are a pharmaceutical composition containing the polypeptide or nucleic acid and a pharmaceutically acceptable carrier, and a method for treating a cellular proliferative disorder.